The FDA biologics database lists a supplement dated 25 September 2026 to the licence for adalimumab-aqvh, a biosimilar marketed as Yusimry. The record gives the product and applicant but not the content of the change.
Nothing in the record indicates a safety finding.
- The supplement relates to BLA 761216 for adalimumab-aqvh (Yusimry).
- It was recorded on 25 September 2026.
- Supplements can cover labelling, presentation or manufacturing changes.
- Several adalimumab biosimilars are marketed in India; this US record does not affect them.
Why it matters
Biosimilar labels change often, including interchangeability and presentation, which can affect pharmacy substitution.
Don't overread it
A licence supplement is not a new indication, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free